Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ZEN003694 · 1 trial · 3 indications
Confirmed complete response or partial response by RECIST 1.1. Per RECIST v1.1. Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. Partial Response (PR): At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters.
| Arm | Type | Description |
|---|---|---|
| ZEN003694 + Talazoparib | EXPERIMENTAL | ZEN003694: 48.0 mg daily (oral) in 28-day cycles Talazoparib: 0.75 mg daily (oral) at the same time as ZEN003694 |
| Name | Type | Description |
|---|---|---|
| ZEN003694 | DRUG | ZEN003694 has shown promising activity in the treatment of solid tumors and hematologic (blood) cancers by reducing the multiplication of cancer cells. |
| Talazoparib | DRUG | Talazoparib kills cancer cells by inhibiting and trapping the enzyme PARP, which is known to be involved in the development of many types of cancers. |
Inclusion Criteria: 1. Females age ≥ 18 years (at time of signing informed consent) 2. ECOG status 0 or 1 3. Pathologically documented ovarian, fallopian tube, or primary peritoneal carcinoma. 4. Prior therapy with PARPi either as maintenance or therapeutic settings. 5. All recurrent ovarian cancer...
Top 20 of 59 competitors
ZEN003694 is an investigational small molecule being studied for the treatment of recurrent ovarian cancer, including peritoneal and fallopian tube cancers. It is currently in Phase 2 clinical development and is not yet approved by the FDA.
ZEN003694 is a small molecule that targets BET proteins, which are epigenetic regulators involved in gene expression. By inhibiting BET proteins, ZEN003694 aims to disrupt cancer cell growth and survival pathways relevant to ovarian cancer.
ZEN003694 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is currently in Phase 2 clinical trials for ovarian cancer.
ZEN003694 is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by the FDA and is still being evaluated for safety and efficacy in patients with recurrent ovarian cancer.
ZEN003694 is being studied in a Phase 2 clinical trial with the identifier NCT05071937. This trial is recruiting female patients aged 18 years and older with recurrent ovarian, peritoneal, or fallopian tube cancer, and is being conducted in the United States.
No, ZEN003694 is not the same as talazoparib. ZEN003694 is a BET inhibitor, while talazoparib is a PARP inhibitor. In the ongoing clinical trial NCT05071937, ZEN003694 is being combined with talazoparib to evaluate the combination's effect in patients with recurrent ovarian cancer.